Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Neuroscience Bulletin ; (6): 951-962, 2018.
Article in English | WPRIM | ID: wpr-777021

ABSTRACT

Fluoxetine, an anti-depressant drug, has recently been shown to provide neuroprotection in central nervous system injury, but its roles in subarachnoid hemorrhage (SAH) remain unclear. In this study, we aimed to evaluate whether fluoxetine attenuates early brain injury (EBI) after SAH. We demonstrated that intraperitoneal injection of fluoxetine (10 mg/kg per day) significantly attenuated brain edema and blood-brain barrier (BBB) disruption, microglial activation, and neuronal apoptosis in EBI after experimental SAH, as evidenced by the reduction of brain water content and Evans blue dye extravasation, prevention of disruption of the tight junction proteins zonula occludens-1, claudin-5, and occludin, a decrease of cells staining positive for Iba-1, ED-1, and TUNEL and a decline in IL-1β, IL-6, TNF-α, MDA, 3-nitrotyrosine, and 8-OHDG levels. Moreover, fluoxetine significantly improved the neurological deficits of EBI and long-term sensorimotor behavioral deficits following SAH in a rat model. These results indicated that fluoxetine has a neuroprotective effect after experimental SAH.


Subject(s)
Animals , Male , Rats , Apoptosis , Blood-Brain Barrier , Brain Edema , Drug Therapy , Cytokines , Genetics , Metabolism , Disease Models, Animal , Fluoxetine , Pharmacology , Therapeutic Uses , In Situ Nick-End Labeling , Neuroprotective Agents , Pharmacology , Therapeutic Uses , Pain Measurement , Psychomotor Performance , RNA, Messenger , Metabolism , Rats, Sprague-Dawley , Subarachnoid Hemorrhage , Drug Therapy , Pathology , Time Factors , Vasospasm, Intracranial , Drug Therapy
SELECTION OF CITATIONS
SEARCH DETAIL